Safety Study of Cenderitide in Stable Chronic Heart Failure

Key Inclusion Criteria: * Male or female, ≥ 18 years of age * Body Mass Index (BMI) of 18-40 kg/m2, inclusive * Current or historical New York Heart Association (NYHA) functional class ≥ II * At least one of the following: documented systolic heart failure with an ejection fraction (EF) ≤ 40% and/or a historical measurement of plasma BNP ≥ 150 pg/mL (or NT-proBNP ≥ 600 pg/mL) * Systolic blood pressure 100-160 mmHg * Stable and compliant treatment with oral heart failure medications for at least 4 weeks prior to Screening Key Exclusion Criteria: * Known hypersensitivity or allergy to natriuretic peptide or its components, nesiritide, other natriuretic peptides or related compounds * Current clinical diagnosis of acute decompensated heart failure (ADHF) * Clinical diagnosis of acute coronary syndrome (ACS) within 30 days prior to Screening. * Symptomatic postural hypotension * Evidence of uncorrected volume or sodium ≤ 130 mmol/L or other condition that would predispose the patient to adverse events * Clinically significant aortic or mitral valve stenosis * Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns) * Severe renal failure defined as creatinine clearance \< 45 mL/min as estimated by either the Cockcroft-Gault or the MDRD equations * Significant pulmonary disease (e.g., history of oral daily steroid dependency, history of Carbon Dioxide (CO2) retention or need for intubation for acute exacerbation, or currently receiving IV steroids) * Known hepatic impairment as indicated by any of the following: A) total bilirubin \> 3 mg/dL; B) albumin \< 2.8 mg/dL, with other signs or symptoms of hepatic dysfunction; C) increased ammonia levels, if performed, with other signs or symptoms of hepatic dysfunction